EcoDrugPlus

Gamma-Aminobutyric Acid (Gaba) B Receptor, 2

Ensembl ID : ENSDLAG00005022337
Gene Symbol: GABBR2
1 Cross references
208 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha1

Ensembl ID : ENSDLAG00005011616
Gene Symbol: GABRA1
1 Cross references
202 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha4

Ensembl ID : ENSDLAG00005034250
Gene Symbol: GABRA4
1 Cross references
201 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha5

Ensembl ID : ENSDLAG00005017107
Gene Symbol: GABRA5
1 Cross references
207 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha6

Ensembl ID : ENSDLAG00005011772
Gene Symbol: GABRA6
1 Cross references
196 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha6a

Ensembl ID : ENSDLAG00005018177
Gene Symbol: GABRA6A
1 Cross references
195 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Beta2

Ensembl ID : ENSDLAG00005011797
Gene Symbol: GABRB2
1 Cross references
177 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Beta2a

Ensembl ID : ENSDLAG00005018021
Gene Symbol: GABRB2A
1 Cross references
200 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Beta3

Ensembl ID : ENSDLAG00005023822
Gene Symbol: GABRB3
1 Cross references
192 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Beta3

Ensembl ID : ENSDLAG00005017323
Gene Symbol: GABRB3
1 Cross references
199 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma2

Ensembl ID : ENSDLAG00005011309
Gene Symbol: GABRG2
1 Cross references
213 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma3

Ensembl ID : ENSDLAG00005017038
Gene Symbol: GABRG3
1 Cross references
222 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).